Division of Rheumatology, Children's Hospital of Philadelphia, PA, and Division of Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, USA.
Division of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, MA, and Division of Rheumatology, Department of Pediatrics, Center for Pediatric Clinical Effectiveness, University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, PA, USA.
Clin Exp Rheumatol. 2023 Jul;41(7):1553-1560. doi: 10.55563/clinexprheumatol/3bu1sf. Epub 2023 Apr 6.
Concomitant arthritis may increase risk of chronic opioid use in youngsters with IBD. We aimed to assess trends and clinical features associated with opioid use in children with IBD-related arthritis.
Adolescents under 18 years of age with IBD-related arthritis, at least 1 year of continuous enrolment, and at least 1 pharmacy claim in the Truven Health MarketScan Claims and Encounter Database were included. Subjects were identified using previously validated algorithms consisting of ICD codes, pharmacy claims and procedure codes. The primary outcome was chronic opioid exposure. Temporal trends in opioid exposure were tested using the Cuzick-Wilcoxon test. The association of chronic opioid use and baseline covariates in the IBD and IBD-arthritis cohorts were examined using multivariable logistic regression models.
14,943 adolescents with IBD, 480 of whom had arthritis, were included. Chronic opioid use was non-trivial in youngsters with IBD-related arthritis, higher than that of total IBD cohort (12.3% vs. 5%) and remained stable over the years of study. Using multivariable regression, joint pain and arthritis were significantly associated with chronic opioid exposure in young people with IBD. Among IBD-related arthritis patients older age, public insurance, gastrointestinal surgery, hospitalisation and psychiatric comorbidities were significantly associated with chronic opioid use.
Chronic opioid use in adolescents with IBD-related arthritis was higher than that of total IBD cohort but stable over the years of study. Future study is needed to explore ways to optimise non-narcotic pain management strategies and ensuring appropriate use of opioids when necessary.
合并性关节炎可能会增加青少年炎症性肠病(IBD)患者慢性使用阿片类药物的风险。本研究旨在评估与 IBD 相关关节炎儿童使用阿片类药物相关的趋势和临床特征。
本研究纳入了年龄在 18 岁以下、患有 IBD 相关关节炎、至少连续 1 年登记、并且在 Truven Health MarketScan 索赔和就诊数据库中有至少 1 次药物索赔的青少年患者。采用先前验证的算法,包括 ICD 代码、药物索赔和程序代码来识别患者。主要结局是慢性阿片类药物暴露。使用 Cuzick-Wilcoxon 检验来测试阿片类药物暴露的时间趋势。使用多变量逻辑回归模型,检验 IBD 和 IBD 关节炎队列中慢性阿片类药物使用与基线协变量的相关性。
共纳入 14943 名患有 IBD 的青少年,其中 480 名患有关节炎。患有 IBD 相关关节炎的青少年中,慢性阿片类药物的使用率较高(12.3%对 5%),且在研究期间保持稳定。使用多变量回归,关节疼痛和关节炎与青少年 IBD 患者慢性阿片类药物暴露显著相关。在 IBD 相关关节炎患者中,年龄较大、公共保险、胃肠手术、住院和精神共病与慢性阿片类药物使用显著相关。
患有 IBD 相关关节炎的青少年慢性阿片类药物使用率高于总 IBD 队列,但在研究期间保持稳定。未来需要进一步研究,以探索优化非阿片类药物疼痛管理策略和在必要时确保阿片类药物合理使用的方法。